Literature DB >> 27764878

Environmental and Genetic Risk Factors Associated with Venous Thromboembolism.

Marta Crous-Bou1, Laura B Harrington2, Christopher Kabrhel3.   

Abstract

Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism, and a combination of environmental and genetic risk factors contributes to VTE risk. Within environmental risk factors, some are provoking (e.g., cancer, surgery, trauma or fracture, immobilization, pregnancy and the postpartum period, long-distance travel, hospitalization, catheterization, and acute infection) and others are nonprovoking (e.g., age, sex, race/ethnicity, body mass index and obesity, oral contraceptive or hormone therapy use, corticosteroid use, statin use, diet, physical activity, sedentary time, and air pollution). Additionally, VTE has a strong genetic basis, with approximately 50 to 60% of the variance in VTE incidence attributed to genetic effects. Some genetic susceptibility variants that contribute to risk have been identified in candidate genes, mostly related to the clotting system and responsible for inherited hypercoagulable states (e.g., factor V Leiden, prothrombin, fibrinogen gamma, or blood group non-O). Other susceptibility single-nucleotide polymorphisms have been identified from genome-wide association studies, such as the two new loci in TSPAN15 (rs78707713) and SCL44A2 (rs2288904) genes. Risk factors are not always associated with VTE in isolation; however, and an understanding of how environmental and genetic factors interact may provide insight into the pathophysiology of VTE, possibly identifying opportunities for targeted prevention and treatment. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27764878      PMCID: PMC5146955          DOI: 10.1055/s-0036-1592333

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  151 in total

1.  ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden.

Authors:  V M Morelli; M C H De Visser; H L Vos; R M Bertina; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

2.  Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures.

Authors:  T Matsui; K Titani; T Mizuochi
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

3.  Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution.

Authors:  Elisabeth Mazoyer; Laurent Ripoll; René Gueguen; Laurence Tiret; Jean-Philippe Collet; Claire Bal dit Sollier; Jacqueline Roussi; Ludovic Drouet
Journal:  Blood Coagul Fibrinolysis       Date:  2009-10       Impact factor: 1.276

4.  ABO blood-groups and the visual outcome of a retinal venous occlusion.

Authors:  J C Parr; L E White
Journal:  Trans Ophthalmol Soc N Z       Date:  1978

5.  High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis.

Authors:  Mohamed Baba-Ahmed; Grégoire Le Gal; Francis Couturaud; Karine Lacut; Emmanuel Oger; Christophe Leroyer
Journal:  Thromb Haemost       Date:  2007-02       Impact factor: 5.249

Review 6.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

7.  Familial segregation of venous thromboembolism.

Authors:  J A Heit; M A Phelps; S A Ward; J P Slusser; T M Petterson; M De Andrade
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

Review 8.  The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

Authors:  Antonio Marchiori; Laura Mosena; Martin H Prins; Paolo Prandoni
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

9.  Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.

Authors:  Nicholas L Smith; Marc Blondon; Kerri L Wiggins; Laura B Harrington; Astrid van Hylckama Vlieg; James S Floyd; Melody Hwang; Joshua C Bis; Barbara McKnight; Kenneth M Rice; Thomas Lumley; Frits R Rosendaal; Susan R Heckbert; Bruce M Psaty
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

10.  Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.

Authors:  Nicholas L Smith; Ming-Huei Chen; Abbas Dehghan; David P Strachan; Saonli Basu; Nicole Soranzo; Caroline Hayward; Igor Rudan; Maria Sabater-Lleal; Joshua C Bis; Moniek P M de Maat; Ann Rumley; Xiaoxiao Kong; Qiong Yang; Frances M K Williams; Veronique Vitart; Harry Campbell; Anders Mälarstig; Kerri L Wiggins; Cornelia M Van Duijn; Wendy L McArdle; James S Pankow; Andrew D Johnson; Angela Silveira; Barbara McKnight; Andre G Uitterlinden; Nena Aleksic; James B Meigs; Annette Peters; Wolfgang Koenig; Mary Cushman; Sekar Kathiresan; Jerome I Rotter; Edwin G Bovill; Albert Hofman; Eric Boerwinkle; Geoffrey H Tofler; John F Peden; Bruce M Psaty; Frank Leebeek; Aaron R Folsom; Martin G Larson; Timothy D Spector; Alan F Wright; James F Wilson; Anders Hamsten; Thomas Lumley; Jacqueline C M Witteman; Weihong Tang; Christopher J O'Donnell
Journal:  Circulation       Date:  2010-03-15       Impact factor: 29.690

View more
  40 in total

Review 1.  Is tofacitinib a game-changing drug for ulcerative colitis?

Authors:  Fernando Magro; Maria Manuela Estevinho
Journal:  United European Gastroenterol J       Date:  2020-06-18       Impact factor: 4.623

2.  Pre-Operative, Intra-Operative, and Post-Operative Factors Associated with Post-Discharge Venous Thromboembolism Following Colorectal Cancer Resection.

Authors:  Cary Jo R Schlick; Jessica Y Liu; Anthony D Yang; David J Bentrem; Karl Y Bilimoria; Ryan P Merkow
Journal:  J Gastrointest Surg       Date:  2019-08-16       Impact factor: 3.452

3.  Interaction of a genetic risk score with physical activity, physical inactivity, and body mass index in relation to venous thromboembolism risk.

Authors:  Jihye Kim; Peter Kraft; Kaitlin A Hagan; Laura B Harrington; Sara Lindstroem; Christopher Kabrhel
Journal:  Genet Epidemiol       Date:  2018-03-08       Impact factor: 2.135

4.  Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study.

Authors:  Sara Lindström; Marine Germain; Marta Crous-Bou; Erin N Smith; Pierre-Emmanuel Morange; Astrid van Hylckama Vlieg; Hugoline G de Haan; Daniel Chasman; Paul Ridker; Jennifer Brody; Mariza de Andrade; John A Heit; Weihong Tang; Immaculata DeVivo; Francine Grodstein; Nicholas L Smith; David Tregouet; Christopher Kabrhel
Journal:  Hum Genet       Date:  2017-05-20       Impact factor: 4.132

Review 5.  Statins as a preventative therapy for venous thromboembolism.

Authors:  Alex Wallace; Hassan Albadawi; Peter Hoang; Andrew Fleck; Sailendra Naidu; Grace Knuttinen; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

6.  Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Authors:  Nicholas S Roetker; Richard F MacLehose; Ron C Hoogeveen; Christie M Ballantyne; Saonli Basu; Mary Cushman; Aaron R Folsom
Journal:  Thromb Haemost       Date:  2018-10-08       Impact factor: 5.249

Review 7.  e-thrombosis: epidemiology, physiopathology and rationale for preventing computer-related thrombosis.

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Emmanuel J Favaloro
Journal:  Ann Transl Med       Date:  2018-09

8.  Sport and Venous Thromboembolism—Site, Accompanying Features, Symptoms, and Diagnosis.

Authors:  Thomas Hilberg; Pia Ransmann; Thorsten Hagedorn
Journal:  Dtsch Arztebl Int       Date:  2021-03-19       Impact factor: 5.594

9.  Risk factors for stent graft thrombosis after transjugular intrahepatic portosystemic shunt creation.

Authors:  Younes Jahangiri; Timothy Kerrigan; Lei Li; Dominik Prosser; Anantnoor Brar; Johnathan Righetti; Ryan C Schenning; John A Kaufman; Khashayar Farsad
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

10.  Acute Pulmonary Embolism in Patients with and without COVID-19.

Authors:  Antonin Trimaille; Anaïs Curtiaud; Kensuke Matsushita; Benjamin Marchandot; Jean-Jacques Von Hunolstein; Chisato Sato; Ian Leonard-Lorant; Laurent Sattler; Lelia Grunebaum; Mickaël Ohana; Patrick Ohlmann; Laurence Jesel; Olivier Morel
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.